Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report

Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report

Abstract Background Pembrolizumab is an immune checkpoint inhibitor and is an anti-human programmed cell death-1 (PD-1) monoclonal antibody. Pembrolizumab is used for non-small cell lung carcinoma with high programmed cell death ligand-1 (PD-L1) expression. It has been found that better overall surv...

Full description

Bibliographic Details
Main Authors: Shoki Sato, Naoto Senmaru, Keita Ishido, Takahiro Saito, Saseem Poudel, Jun Muto, Yasuhito Syouji, Ryunosuke Hase, Satoshi Hirano
Format: Article
Language:English
Published: SpringerOpen 2019-10-01
Series:Surgical Case Reports
Subjects:
Pembrolizumab
Small intestinal perforation
Non-small cell lung carcinoma metastasis
Online Access:http://link.springer.com/article/10.1186/s40792-019-0730-6

Internet

http://link.springer.com/article/10.1186/s40792-019-0730-6

Similar Items